{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:09:58Z","timestamp":1785607798260,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11920-018-0881-3","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T22:31:12Z","timestamp":1520807472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and\/or Frequent in Bipolar Disorder"],"prefix":"10.1007","volume":"20","author":[{"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"issue":"12","key":"881_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/NDT.S100846","volume":"31","author":"M Fornaro","year":"2016","unstructured":"\u2022\u2022 Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat. 2016;31(12):719\u201335. Systematic review of the high frequency of polypharmacy in bipolar disorder.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"881_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.08m04301","volume":"70","author":"JF Goldberg","year":"2009","unstructured":"Goldberg JF, Brooks JO 3rd, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70(2):155\u201362. \n                      https:\/\/doi.org\/10.4088\/JCP.08m04301\n                      \n                    .","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"881_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"GM Goodwin","year":"2016","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495\u2013553. \n                      https:\/\/doi.org\/10.1177\/0269881116636545\n                      \n                    .","journal-title":"J Psychopharmacol"},{"issue":"1","key":"881_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1\u201344. \n                      https:\/\/doi.org\/10.1111\/bdi.12025\n                      \n                    .","journal-title":"Bipolar Disord"},{"issue":"2","key":"881_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ijnp\/pyw109","volume":"20","author":"KN Fountoulakis","year":"2017","unstructured":"Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20(2):180\u201395. \n                      https:\/\/doi.org\/10.1093\/ijnp\/pyw109\n                      \n                    .","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"881_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/15622975.2013.770551","volume":"14","author":"H Grunze","year":"2013","unstructured":"Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, M\u00f6ller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154\u2013219. \n                      https:\/\/doi.org\/10.3109\/15622975.2013.770551\n                      \n                    .","journal-title":"World J Biol Psychiatry"},{"key":"881_CR7","unstructured":"National Institute for Health and Clinical Excellence. Bipolar disorder (update): the management of bipolar disorder in adults, children and adolescents in primary and secondary care. (Clinical Guideline 185.) 2014. \n                      http:\/\/guidance.nice.org.uk\/CG185\n                      \n                    ."},{"issue":"12","key":"881_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0004867415617657","volume":"49","author":"GS Malhi","year":"2015","unstructured":"Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087\u2013206. \n                      https:\/\/doi.org\/10.1177\/0004867415617657\n                      \n                    .","journal-title":"Aust N Z J Psychiatry"},{"issue":"7","key":"881_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.4088\/JCP.15cs09841","volume":"77","author":"MJ Ostacher","year":"2016","unstructured":"Ostacher MJ, Tandon R, Suppes T. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry. 2016;77(7):920\u20136. \n                      https:\/\/doi.org\/10.4088\/JCP.15cs09841\n                      \n                    .","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"881_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/pcn.12060","volume":"67","author":"S Kanba","year":"2013","unstructured":"Kanba S, Kato T, Terao T, Yamada K, Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders, 2012. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci. 2013;67(5):285\u2013300. \n                      https:\/\/doi.org\/10.1111\/pcn.12060\n                      \n                    .","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1-02","key":"881_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0043-117891","volume":"51","author":"J Leon de","year":"2018","unstructured":"de Leon J. A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018;51(1-02):63-68. \n                      https:\/\/doi.org\/10.1055\/s-0043-117891\n                      \n                    .","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"881_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","volume":"100","author":"E Spina","year":"2007","unstructured":"Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4\u201322. \n                      https:\/\/doi.org\/10.1111\/j.1742-7843.2007.00017.x\n                      \n                    .","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"881_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1517\/17425255.2012.660918","volume":"8","author":"J Leon de","year":"2012","unstructured":"de Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8(3):311\u201334. \n                      https:\/\/doi.org\/10.1517\/17425255.2012.660918\n                      \n                    .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"881_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1517\/17425255.2014.885504","volume":"10","author":"E Spina","year":"2014","unstructured":"\u2022 Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10(5):721\u201346. First attempt to explore pharmacokinetic and pharmacodynamic drug-drug interactions between new antipsychotics and new antidepressants. \n                      https:\/\/doi.org\/10.1517\/17425255.2014.885504\n                      \n                    .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"881_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","volume":"10","author":"D Italiano","year":"2014","unstructured":"\u2022 Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457\u201389. First attempt to explore pharmacokinetic and pharmacodynamic drug-drug interactions between antiepileptic and antidepressant drugs. \n                      https:\/\/doi.org\/10.1517\/17425255.2014.956081\n                      \n                    .","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"881_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","volume":"12","author":"E Spina","year":"2016","unstructured":"Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407\u201322. \n                      https:\/\/doi.org\/10.1517\/17425255.2016.1154043\n                      \n                    .","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"881_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","volume":"106","author":"E Spina","year":"2016","unstructured":"\u2022 Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72\u201386. This review article includes tables with a summary of dose correction factors for the pharmacokinetic drug-drug interactions used in the tables of this new article. \n                      https:\/\/doi.org\/10.1016\/j.phrs.2016.02.014\n                      \n                    .","journal-title":"Pharmacol Res"},{"key":"881_CR18","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Spina E, de Leon J. Potentially clinically relevant pharmacodynamics interactions between antiepileptic drugs and psychotropic drugs: an update. Curr Pharm Des. 2017;23 \n                      https:\/\/doi.org\/10.2174\/1381612823666170809102258\n                      \n                    . First attempt to explore pharmacodynamic drug-drug interactions of antiepileptic drugs with the main psychiatric drugs.","DOI":"10.2174\/1381612823666170809102258"},{"issue":"1-02","key":"881_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):e1. \n                      https:\/\/doi.org\/10.1055\/s-0043-116492\n                      \n                    .","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"881_CR20","first-page":"136","volume":"44","author":"F Lana","year":"2016","unstructured":"Lana F, Mart\u00ed-Bonany J, Fuster J, de Leon J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Esp Psiquiatr. 2016;44(4):136\u201344.","journal-title":"Actas Esp Psiquiatr"},{"issue":"2","key":"881_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.rpsm.2014.10.006","volume":"8","author":"J Leon de","year":"2015","unstructured":"de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015;8(2):97\u2013115. \n                      https:\/\/doi.org\/10.1016\/j.rpsm.2014.10.006\n                      \n                    .","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"3","key":"881_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.rpsm.2014.10.005","volume":"8","author":"J Leon de","year":"2015","unstructured":"de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8(3):167\u201388. \n                      https:\/\/doi.org\/10.1016\/j.rpsm.2014.10.005\n                      \n                    .","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"2","key":"881_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bone.2008.10.001","volume":"44","author":"A Zamani","year":"2009","unstructured":"Zamani A, Omrani GR, Nasab MM. Lithium\u2019s effect on bone mineral density. Bone. 2009;44(2):331\u20134. \n                      https:\/\/doi.org\/10.1016\/j.bone.2008.10.001\n                      \n                    .","journal-title":"Bone"},{"issue":"5","key":"881_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00774-016-0783-6","volume":"35","author":"Y Jin","year":"2017","unstructured":"Jin Y, Xu L, Hu X, Liao S, Pathak JL, Liu J. Lithium chloride enhances bone regeneration and implant osseointegration in osteoporotic conditions. J Bone Miner Metab. 2017;35(5):497\u2013503.","journal-title":"J Bone Miner Metab."},{"issue":"8","key":"881_CR25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40262-016-0370-y","volume":"55","author":"PR Finley","year":"2016","unstructured":"Finley PR. Drug interactions with lithium: an update. Clin Pharmacokinet. 2016;55(8):925\u201341. \n                      https:\/\/doi.org\/10.1007\/s40262-016-0370-y\n                      \n                    .","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"881_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1039\/C7MT00203C","volume":"9","author":"M Roux","year":"2017","unstructured":"\u2022 Roux M, Dosseto A. From direct to indirect lithium targets: a comprehensive review of omics data. Metallomics. 2017;9(10):1326\u201351. \n                      https:\/\/doi.org\/10.1039\/c7mt00203c\n                      \n                    . Comprehensive update of complex lithium pharmacodynamic actions.","journal-title":"Metallomics"},{"issue":"542862","key":"881_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/542862","volume":"2015","author":"J Jackson","year":"2015","unstructured":"Jackson J, McCollum B, Ognibene J, Diaz FJ, de Leon J. Three patients needing high doses of valproic acid to get therapeutic concentrations. Case Rep Psychiatry. 2015;2015(542862):1\u201312. \n                      https:\/\/doi.org\/10.1155\/2015\/542862\n                      \n                    .","journal-title":"Case Rep Psychiatry"},{"issue":"9","key":"881_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","volume":"10","author":"G Schoretsanitis","year":"2017","unstructured":"Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10(9):965\u201381. \n                      https:\/\/doi.org\/10.1080\/17512433.2017.1345623\n                      \n                    .","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"881_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40263-014-0197-8","volume":"28","author":"Y Ogawa","year":"2014","unstructured":"\u2022 Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination\/augmentation therapy versus monotherapy. CNS Drugs. 2014;28(11):989\u20131003. Systematic review of combined therapy versus monotherapy in mania. \n                      https:\/\/doi.org\/10.1007\/s40263-014-0197-8\n                      \n                    .","journal-title":"CNS Drugs"},{"issue":"12","key":"881_CR30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/0004867415614109","volume":"49","author":"P Glue","year":"2015","unstructured":"\u2022 Glue P, Herbison P. Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: network meta-analysis. Aust N Z J Psychiatry. 2015;49(12):1215\u201320. Systematic review of combined therapy versus monotherapy in mania. \n                      https:\/\/doi.org\/10.1177\/0004867415614109\n                      \n                    .","journal-title":"Aust N Z J Psychiatry"},{"issue":"8","key":"881_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1517\/14740338.2015.1053457","volume":"14","author":"B Galling","year":"2015","unstructured":"\u2022 Galling B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015;14(8):1181\u201399. Systematic review of combined therapy versus monotherapy in mania or bipolar depression. \n                      https:\/\/doi.org\/10.1517\/14740338.2015.1053457\n                      \n                    .","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"881_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00023210-200620010-00003","volume":"20","author":"D Lin","year":"2006","unstructured":"Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006;20(1):29\u201342. \n                      https:\/\/doi.org\/10.2165\/00023210-200620010-00003\n                      \n                    .","journal-title":"CNS Drugs"},{"issue":"12","key":"881_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/cns.12017","volume":"18","author":"PA Geoffroy","year":"2012","unstructured":"Geoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther. 2012;18(12):957\u201364. \n                      https:\/\/doi.org\/10.1111\/cns.12017\n                      \n                    .","journal-title":"CNS Neurosci Ther"},{"issue":"02","key":"881_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1192\/bjp.182.2.141","volume":"182","author":"LN Yatham","year":"2003","unstructured":"Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182(02):141\u20137. \n                      https:\/\/doi.org\/10.1192\/bjp.182.2.141\n                      \n                    .","journal-title":"Br J Psychiatry"},{"issue":"3","key":"881_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/JCP.0000000000000115","volume":"34","author":"J Leon de","year":"2014","unstructured":"de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder. J Clin Psychopharmacol. 2014;34(3):291\u20136. \n                      https:\/\/doi.org\/10.1097\/JCP.0000000000000115\n                      \n                    .","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"881_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/JCP.0000000000000093","volume":"34","author":"J Leon de","year":"2014","unstructured":"de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: focus on epilepsy. J Clin Psychopharmacol. 2014;34(2):177\u201383. \n                      https:\/\/doi.org\/10.1097\/JCP.0000000000000093\n                      \n                    .","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"881_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1192\/bjp.bp.107.041301","volume":"192","author":"M Tohen","year":"2008","unstructured":"Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008;192(2):135\u201343. \n                      https:\/\/doi.org\/10.1192\/bjp.bp.107.041301\n                      \n                    .","journal-title":"Br J Psychiatry"},{"issue":"5","key":"881_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1185\/03007995.2012.666961","volume":"28","author":"H Katagiri","year":"2012","unstructured":"Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic\/mixed episodes for Japanese patients with bipolar I disorder. Curr Med Res Opin. 2012;28(5):701\u201313. \n                      https:\/\/doi.org\/10.1185\/03007995.2012.666961\n                      \n                    .","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"881_CR39","first-page":"49","volume":"5","author":"RH Weisler","year":"2008","unstructured":"Weisler RH, Kalali AH, Cutler AJ, Gazda TD, Ginsberg L. Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. Psychiatry (Edgmont). 2008;5(5):49\u201360.","journal-title":"Psychiatry (Edgmont)"},{"issue":"8","key":"881_CR40","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1017\/S1461145711000885","volume":"14","author":"E Vieta","year":"2011","unstructured":"Vieta E, G\u00fcnther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029\u201349. \n                      https:\/\/doi.org\/10.1017\/S1461145711000885\n                      \n                    .","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"881_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00213-010-2056-8","volume":"213","author":"D Popovic","year":"2011","unstructured":"Popovic D, Reinares M, Amann B, Salamero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology. 2011;213(4):657\u201367. \n                      https:\/\/doi.org\/10.1007\/s00213-010-2056-8\n                      \n                    .","journal-title":"Psychopharmacology"},{"key":"881_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jad.2013.08.024","volume":"152-154","author":"M Buoli","year":"2014","unstructured":"Buoli M, Serati M, Altamura AC. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. J Affect Disord. 2014;152-154:12\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jad.2013.08.024\n                      \n                    .","journal-title":"J Affect Disord"},{"issue":"8","key":"881_CR43","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/mp.2015.158","volume":"21","author":"LN Yatham","year":"2016","unstructured":"Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to moo stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry. 2016;21(8):1050\u20136. \n                      https:\/\/doi.org\/10.1038\/mp.2015.158\n                      \n                    .","journal-title":"Mol Psychiatry"},{"issue":"31","key":"881_CR44","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.3969\/j.issn.1673-5374.2013.31.009","volume":"8","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yang H, Yang S, Liang W, Dai P, Wang C, et al. Antidepressants for bipolar disorder: a meta-analysis of randomized, double-blind, controlled trials. Neural Regen Res. 2013;8(31):2962\u201374. \n                      https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.31.009\n                      \n                    .","journal-title":"Neural Regen Res"},{"issue":"12","key":"881_CR45","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","volume":"3","author":"A McGirr","year":"2016","unstructured":"\u2022 McGirr A, V\u00f6hringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138\u201346. Systematic review of combined therapy versus monotherapy in bipolar depression. \n                      https:\/\/doi.org\/10.1016\/S2215-0366(16)30264-4\n                      \n                    .","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"881_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-0033-1364004","volume":"47","author":"S K\u00f6hler","year":"2014","unstructured":"K\u00f6hler S, Gaus S, Bschor T. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry. 2014;47(2):53\u20139. \n                      https:\/\/doi.org\/10.1055\/s-0033-1364004\n                      \n                    .","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"881_CR47","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S0165-0327(14)70006-0","volume":"169","author":"TA Ketter","year":"2014","unstructured":"Ketter TA, Miller S, Dell'Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord. 2014;169(Suppl 1):S24\u201333. \n                      https:\/\/doi.org\/10.1016\/S0165-0327(14)70006-0\n                      \n                    .","journal-title":"J Affect Disord"},{"issue":"2","key":"881_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/JCP.0b013e3182491383","volume":"32","author":"J Leon de","year":"2012","unstructured":"de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012;32(2):153\u201364. \n                      https:\/\/doi.org\/10.1097\/JCP.0b013e3182491383\n                      \n                    .","journal-title":"J Clin Psychopharmacol"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-018-0881-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-018-0881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-018-0881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T21:16:27Z","timestamp":1552338987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-018-0881-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s11920-018-0881-3","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"12 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"17"}}